Publication Name	World Journal of Diabetes
Manuscript ID	94124
Country	Taiwan

Received	2024-03-11 23:30
Peer-Review Started	2024-03-11 23:30
To Make the First Decision
Return for Revision	2024-09-19 09:17
Revised	2024-09-27 16:40
Second Decision	2024-10-29 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-29 08:12
Articles in Press	2024-10-29 08:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-05 08:45
Publish the Manuscript Online	2024-11-18 03:30

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Letter to the Editor
Article Title	Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies
Manuscript Source	Invited Manuscript
All Author List	Chun-Yao Cheng, Wen-Rui Hao, Ju-Chi Liu and Tzu-Hurng Cheng
ORCID	Author(s) ORCID Number Tzu-Hurng Cheng http://orcid.org/0000-0002-9155-4169
Funding Agency and Grant Number
Corresponding Author	Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404333, Taiwan. thcheng@mail.cmu.edu.tw
Key Words	Diabetic cardiomyopathy; Teneligliptin; Nucleotide-binding oligomerization domain-like receptor 3 inflammasome; Inflammasome inhibition
Core Tip	Teneligliptin can mitigate diabetic cardiomyopathy (DCM) by inhibiting NOD-like receptor protein 3 inflammasome activation and upregulating AMP-activated protein kinase signaling. This study provides insights into the molecular mechanisms underlying the beneficial effects of teneligliptin for the treatment of DCM.
Publish Date	2024-11-18 03:30
Citation	<p>Cheng CY, Hao WR, Liu JC, Cheng TH. Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies. <i>World J Diabetes</i> 2024; 15(12): 2370-2375</p>
URL	https://www.wjgnet.com/1948-9358/full/v15/i12/2370.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i12.2370

Full Article (PDF)	WJD-15-2370-with-cover.pdf
Manuscript File	94124_Auto_Edited_020042.docx
Answering Reviewers	94124-answering-reviewers.pdf
Audio Core Tip	94124-audio.mp3
Conflict-of-Interest Disclosure Form	94124-conflict-of-interest-statement.pdf
Copyright License Agreement	94124-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	94124-non-native-speakers.pdf
Peer-review Report	94124-peer-reviews.pdf
Scientific Misconduct Check	94124-scientific-misconduct-check.png
Scientific Editor Work List	94124-scientific-editor-work-list.pdf
CrossCheck Report	94124-crosscheck-report.png
CrossCheck Report	94124-crosscheck-report.pdf